Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Completed
Pilot study into low dose naltrexone (LDN) and NAD+ for treatment of patients with post-COVID-19 syndrome.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
01/23/2023
Locations: AgelessRx, Ann Arbor, Michigan
Conditions: Covid19, Long COVID-19, Post-COVID-19 Syndrome